Worldwide: Food and Drugs Law

On February 6, 2026, the US Food and Drug Administration (FDA) announced its intent to take action against compounded GLP-1 medications.

Artificial intelligence is no longer a peripheral tool in personalized medicine. AI is becoming a central driver of how diagnostics...

A bill introduced in the Colorado Senate this session could meaningfully reshape how craft producers across the state share facilities, split costs, and bring new products to market.

On February 11, 2026, Formycon AG and Lotus Pharmaceutical announced the execution of an exclusive license agreement directed to Formycon's pembrolizumab biosimilar candidate, FYB206.

Cowan, Liebowitz & Latman, P.C. celebrates Black History Month by celebrating the pioneering work of Dr. Charles Drew.

The Trump Administration continues to advocate for "Most Favored Nation" (MFN) pharmaceutical drug pricing through executive action and voluntary agreements, but the Administration's high-profile deals may have limited impact. To date, 16 manufacturers have signed voluntary agreements to adopt MFN prices. These deals will only apply to state Medicaid programs and cash-paying consumers, which limits their impact.

The U.S. Food and Drug Administration (FDA) has announced a new enforcement approach that allows food companies...

The push to health care transparency continues.[1] During the first Trump administration, the Centers for Medicare and Medicaid Services ("CMS"), with the Department of Labor ("DOL")...

In legislation enacted on Feb. 3, 2026, Congress reauthorized the rare pediatric disease priority review voucher program, clarified the scope of orphan drug exclusivity...